Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 501 to 510 of 1338 total matches.

Trandolapril: An ACE Inhibitor for Treatment of Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 1996  (Issue 988)
, trandolaprilat, which is primarily responsible for the drug’s ACE-inhibiting activity. Food slows the rate ...
Trandolapril (tran doe la pril; Mavik - Knoll) has become the ninth angiotensin-converting- enzyme (ACE) inhibitor to be approved by the US Food and Drug Administration (FDA) for treatment of hypertension.
Med Lett Drugs Ther. 1996 Nov 22;38(988):104-5 |  Show IntroductionHide Introduction

Zileuton for Asthma

   
The Medical Letter on Drugs and Therapeutics • Feb 28, 1997  (Issue 995)
have not been published. ADVERSE EFFECTS — Alanine aminotransferase activity (ALT) has increased to three times normal ...
Zileuton (zye loo' ton; Zyflo - Abbott), an inhibitor of leukotriene synthesis, has been approved by the US Food and Drug Administration (FDA) for prophylaxis and maintenance treatment of chronic asthma in adults and children more than 12 years old. A related drug—zafirlukast (Accolate), a leukotriene receptor antagonist—was recently reviewed in the Medical Letter (vol. 38, page 111, December 20, 1996). Neither of these drugs is recommended for treatment of acute asthma.
Med Lett Drugs Ther. 1997 Feb 28;39(995):18-9 |  Show IntroductionHide Introduction

An Emergency Contraception Kit

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
containing 21 active tablets. 4. Yellow tablets only of Tri-Levlen or Triphasil, or pink tablets only ...
High doses of estrogens, with or without a progestin, have been used for many years to prevent pregnancy after unprotected coitus (Medical Letter, 31:93, 1989). Now the FDA has approved marketing of the Preven Emergency Contraceptive Kit (Gynetics, Inc.) for this indication. The kit, which will require a prescription, includes four tablets, each containing 50 g of ethinyl estradiol and 0.25 mg of levonorgestrel, and a pregnancy test to rule out a pre-existing pregnancy, which would be a contraindication to taking the hormones.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):102-3 |  Show IntroductionHide Introduction

Citalopram for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 1998  (Issue 1041)
of metoprolol (Lopressor, and others) and the active metabolite of imipramine (Tofranil, and others), both ...
Citalopram hydrobromide (Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for treatment of depression. It is being advertised as having a 'favorable side-effect profile.'
Med Lett Drugs Ther. 1998 Dec 4;40(1041):113-4 |  Show IntroductionHide Introduction

Modafinil for Narcolepsy

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999  (Issue 1049)
Acad Sci, 93:14128, 1996; TM Engber et al, Neuroscience, 87:905, 1998). It increases activity ...
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
Med Lett Drugs Ther. 1999 Mar 26;41(1049):30-1 |  Show IntroductionHide Introduction

Galantamine (Reminyl) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
nicotinic activity remains to be established. PHARMACOKINETICS — Galantamine is rapidly absorbed ...
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase inhibitor approved for this indication.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):53-4 |  Show IntroductionHide Introduction

Belatacept (Nulojix) for Prevention of Renal Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
or tacrolimus. MECHANISM OF ACTION — Activated T-cells (lymphocytes) are a major contributor to immunologic ...
The FDA has approved belatacept (bel at´ a sept; Nulojix – Bristol-Myers Squibb) for prevention of organ rejection in adult patients receiving a kidney transplant.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):98-9 |  Show IntroductionHide Introduction

PDE5 Inhibitors for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2012  (Issue 1383)
before sexual max 10 mg daily 5 mg once daily, not to exceed once activity Severe: not recommended max ...
Sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Med Lett Drugs Ther. 2012 Feb 6;54(1383):10-1 |  Show IntroductionHide Introduction

Omacetaxine (Synribo) for CML (online only)

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
inhibitors, homoharringtonine was the most active agent available for treatment of chronic myeloid leukemia ...
The FDA has approved omacetaxine mepesuccinate (Synribo – Teva), a cephalotaxine known for many years as homoharringtonine, for treatment of adults with chronic or accelerated phase chronic myeloid leukemia (CML) who are no longer responding to, or who could not tolerate, two or more tyrosine kinase inhibitors.
Med Lett Drugs Ther. 2015 May 25;57(1469):e80-1 |  Show IntroductionHide Introduction

A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
. C1INH suppresses the activity of the serine protease plasma kallikrein, preventing generation ...
The FDA has approved Ruconest (Salix), a recombinant analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks in patients with hereditary angioedema (HAE).
Med Lett Drugs Ther. 2016 Mar 28;58(1491):e44-5 |  Show IntroductionHide Introduction